First let me state I am deeply invested in Innovat
Post# of 72440
Patients get better. Simple as that. Remdesivir or not, Brilacidin + SOC or not, most patients get better. If the Brilacidin trial is recruiting 1-3 patients per site per week and most patients recover it will be difficult to recognize, even, a significant difference in progression toward wellness on a site by site anecdotal basis. The entire body of trial data will have to be evaluated before a difference in treatment outcomes and validation of Brilacidin will be recognized.